MUMBAI, India–(Business Wire)–
Sun Pharmaceutical Industries Ltd. announced that together with its affiliates
(“Sun Pharma”) it has executed a settlement agreement with Orion stipulating a
dismissal of the lawsuits filed in the United States against Sun Pharma
regarding submission of Abbreviated New Drug Applications (ANDAs) for generic
versions of Stalevo and Comtan tablets.
Under the terms of the settlement agreement, Sun Pharma will be able to launch
generic versions of 25/100/200 mg and 37.5/150/200 mg strengths of Stalevo
tablets in the US on 1 April 2012. In addition to these strengths, Sun Pharma
will be able to launch generic versions of other strengths of Stalevo product on
2 October 2012 and generic versions of Comtan product on 1 April 2013, unless
certain conditions relating to launch are fulfilled even earlier. The parties
have agreed that Orion will supply these generic product versions to Sun Pharma.
Other terms of the settlement are confidential.
These agreements will be subject to review by the US Federal Trade Commission
and the US Department of Justice.
Stalevo and Comtan are registered trademarks of Orion Corporation.
About Sun Pharmaceutical Industries Ltd.
Established in 1983, listed since 1994 and headquartered in India, Sun
Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:
SUNPHARMA, BSE: 524715) is an international, integrated, speciality
pharmaceutical company. It manufactures and markets a large basket of
pharmaceutical formulations as branded generics as well as generics in India, US
and several other markets across the world. In India, the company is a leader in
niche therapy areas of psychiatry, neurology, cardiology, diabetology,
gastroenterology, orthopedics and ophthalmology. The Company has strong skills
in product development, process chemistry, and manufacturing of complex API, as
well as dosage forms. More information about the company can be found at
Sun Pharmaceutical Industries Ltd.
Tel: +91 22 6645 5645, Xtn 605
Tel Direct: +91 22 66455605
Mobile: +91 98670 10529
Tel: +91 22 6645 5645, Xtn 606
Tel Direct: +91 22 66455606
Mobile: +91 98219 23797
Copyright Business Wire 2010